Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer

Novo Nordisk has intensified its bidding war for obesity biotech Metsera, with Metsera's board declaring Novo's latest offer of up to $10 billion ($86.20 per share) as "superior" to Pfizer's revised bid of up to $8.1 billion ($70 per share). Pfizer, which initially agreed to acquire Metsera, now has two business days to negotiate and has filed lawsuits alleging Novo Nordisk's bid is anticompetitive. This escalating contest highlights the strategic importance of Metsera's promising pipeline of oral and injectable weight-loss treatments, as Pfizer seeks to enter the lucrative market and Novo Nordisk aims to bolster its position amidst fierce competition.

Analysis

Novo Nordisk has escalated its takeover bid for obesity biotech Metsera, with Metsera's board declaring Novo's latest offer of up to $86.20 per share, totaling $10 billion, as "superior." This new proposal represents a significant 159% premium over Metsera's closing price on September 19th, surpassing Pfizer's revised offer of up to $70 per share, or $8.1 billion. Pfizer now has a two-business-day window to negotiate adjustments to its proposal.

This bidding war highlights the intense strategic value of Metsera's pipeline, which includes promising oral and injectable GLP-1 and amylin treatments with potential once-monthly dosing. For Pfizer, Metsera offers a critical entry point into the lucrative weight-loss market, where it has struggled to develop its own products. Novo Nordisk, a market leader, seeks to bolster its position and innovative pipeline amidst increasing competition from Eli Lilly and other emerging players.

The acquisition is complicated by Pfizer's strong opposition, with CEO Albert Bourla labeling Novo Nordisk's offer as "illusory" and alleging antitrust violations, citing a high risk of non-consummation. Pfizer has filed a second lawsuit against both Novo Nordisk and Metsera, asserting anticompetitive behavior. Novo Nordisk, however, maintains its bid complies with all applicable laws and serves the best interests of patients and Metsera's shareholders.

Key Decisions for Investors

• Monitor Pfizer's response within the two-day negotiation window, as a revised bid or intensified legal action could significantly alter the deal's outcome.
• Assess the regulatory and legal risks associated with Pfizer's antitrust allegations, which introduce uncertainty regarding the deal's consummation and potential timeline.
• Evaluate Metsera's fundamental value and pipeline strength, as the intense bidding war underscores the strategic importance of its next-generation obesity treatments, irrespective of the immediate acquisition outcome.
• Consider the broader competitive landscape in the obesity drug market and how the acquisition's resolution will impact the strategic positioning and growth trajectories of both Novo Nordisk and Pfizer.